Eisai to Acquire Morphotek to Expand into Biologic Therapeutics

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Ariana Pelosci

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Kenneth H. Yu, MD, discusses the results from the SHARON trial in pancreatic cancer that were presented at ESMO 2025.

Anne Chiang, MD

October 20th 2025

Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

The phase 3 KEYNOTE-689 trial showed a median EFS of 59.7 months with the pembrolizumab regimen in locally advanced head and neck squamous cell carcinoma.

Tim Cortese

ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma

The phase 3 KEYNOTE-689 trial showed a median EFS of 59.7 months with the pembrolizumab regimen in locally advanced head and neck squamous cell carcinoma.

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

Russ Conroy

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

Related Content

Omar K. Abughanimeh, MBBS;Anthony E. Maida III, PhD, MA, MBA;Sanjive Qazi, PhD;Kate-Lynn Muir, DO;Bhavina Sharma MD;Lynette Smith, PhD;Apar Kishor Ganti, MD

October 30th 2025

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Ariana Pelosci

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Kenneth H. Yu, MD, discusses the results from the SHARON trial in pancreatic cancer that were presented at ESMO 2025.

Anne Chiang, MD

October 20th 2025

Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Tim Cortese

ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma

The phase 3 KEYNOTE-689 trial showed a median EFS of 59.7 months with the pembrolizumab regimen in locally advanced head and neck squamous cell carcinoma.

Russ Conroy